MIRAILAB BIOSCIENCE Inc. has launched its β-Nicotinamide Mononucleotide (β-NMN) supplement brand, “MIRAI LAB,” in the UAE. NMN, found naturally in all living organisms, is believed to have anti-aging and rejuvenating properties, and MIRAI LAB offers a high-concentration “NMN Pure Series.” This expansion into the UAE market broadens the availability of their products, previously sold in Japan, China, the United States, and Singapore, amongst others.
This launch demonstrates the increasing global demand for NMN supplements and positions MIRAILAB to capitalize on this burgeoning market. The UAE, known for its affluent consumer base, presents a lucrative opportunity for the company. Moreover, the ongoing research into NMN’s benefits, including studies funded by the U.S. Department of Defense using MIRAI LAB’s product, adds to the credibility and potential of this supplement category.
MIRAI LAB’s NMN is distinguished by its 99.7% purity, a key factor in its selection for clinical trials. One such trial, published in Science, demonstrated a 25% improvement in muscle insulin sensitivity in postmenopausal women with prediabetes. Further research, also utilizing MIRAI LAB’s NMN and funded by the U.S. Department of Defense, is currently underway with a broader participant group including men. Additionally, animal studies suggest NMN may suppress age-related weight gain by enhancing energy metabolism and fatty acid oxidation. The company initially launched the world’s first NMN product in 2015.
This expansion into the UAE reinforces MIRAILAB’s position as a leader in the NMN supplement market. Continued research and positive clinical trial results could further drive demand for NMN products, benefiting MIRAILAB and potentially shaping the future of anti-aging and wellness strategies. The ongoing promotional sale in the UAE suggests a strategic effort to rapidly penetrate this new market and gain consumer awareness. The combination of scientific backing, high product purity, and strategic market expansion positions MIRAI LAB for continued growth and influence in this evolving field.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
